Heptares Therapeutics
Kerry Barkan began their work experience in 2014 as a PhD student at the University of Warwick, where they stayed until 2017. They then joined the University of Cambridge as a Postdoctoral Research Associate in the Department of Pharmacology in October 2017. In 2020, Kerry Barkan transitioned to industry, working as a Research Scientist at Sosei Heptares. Currently, they hold the position of Senior Scientist I at the same company.
Kerry Barkan earned a Bachelor's Degree in Biological and Biomedical Sciences from the University of Warwick between 2010 and 2013.
This person is not in the org chart
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.